skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Hi Peter and team, I don't hold any of the above stocks and they have done very well the last 2 years. I do own some of your favorites like BAM, TOI, CUS, SHOP and LSPD etc. How would you rank the above stocks and would they be good buy when the dust finally settles.

Regards
Anthony

Read Answer Asked by Anthony on February 25, 2022

Q: Please rank these telemedicine stocks as likely (1) survivor and consolidator, (2) acquiree, (3) flash in the pan and eventually bankrupt. Please include any other Canadian telemedicine stocks that I missed in this list.

Read Answer Asked by Brendon on January 28, 2022

Q: We have very little tech. exposure in our portfolios as a % - so minimal. Own IGM & ARKK in USD portfolio - IGM for 4 years - done very well. In TFSA, own STC, VHI, XIT ETF. All the others are on my list to purchase as not. I would buy equal positions - so, of those we do not own which three would you consider the best in the short and long term. I am mostly a dividend grower investor - companies that increase them every year; however, trying to add a bit of tech. Maybe there others not shown that meet my criteria?

Read Answer Asked by James on August 10, 2021

Q: Could you please provide your comments regarding the above companies. How would you rank them in terms of a 3 year hold as regards risk/growth possibilities.

Thanks

David

Read Answer Asked by david on April 22, 2021

Q: I follow Jason Donville and like 5iresearch recommends similar tech companies as 5i using "the rule of 40". Do you use this rule? Other than his fairly transparent newsletter, is there any way to see exactly what his holdings are in the DKAM Capital Ideas fund?

Read Answer Asked by David on March 23, 2021

Q: Could you please comment on VHI's latest licensing deal.
Thanks as always.

VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce a multi-year large-scale licensing transaction of recently acquired subsidiary Intouch with Health’s (“Intouch”) Synopsis product with South Tees Hospitals NHS Foundation Trust (the “Trust” or “South Tees”).

This transaction is among VitalHub’s largest to-date, comprising a 5-year licensing contract for the Company’s proprietary, award-winning Synopsis platform. From initial questionnaire through to post-operative outcomes, Synopsis provides the necessary tools to enable hospitals to manage the entire pre-operative assessment process digitally – removing paper trails, increasing data security, and delivering significant organizational and economic benefits.

Read Answer Asked by karl on March 03, 2021